Setting 
My Cart
Toggle Nav
Close
  • Menu
  • Setting

EZ Cap™ Golgi-mTurquoise2 Probe mRNA (m1Ψ)

Catalog No.
R1120
Golgi apparatus (Golgi) probes mRNA with cyan fluorescent protein (mTurquoise2), modified by N1-Methylpseudo-UTP (m1Ψ), providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Grouped product items
SizePriceStock Qty
100ug(1mg/mL)
$210.00
In stock
1mg(1mg/mL)
$1,136.00
In stock
5x1mg(1mg/mL)
$4,090.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Golgi-mturquoise2 is a fusion protein, consisting of Golgi apparatus (Golgi) targeting sequence and cyan fluorescent protein (mTurquoise2). mTurquoise2 has high brightness and stability, and is suitable for live cell imaging. By fusing mTurquoise2 with Golgi signal sequences, the distribution and movement of Golgi can be observed in real time in living cells. The high light stability, and low light bleaching properties of Golgi-Mturquoise2 make it ideal for long-term imaging experiments, and useful for studying the role of the Golgi in related processes, such as protein transport, vesicular transport, and cell secretion.

Key features:

Cap1 Structure: The mRNA incorporates a Cap1 analog at the 5' end, ensuring high translation initiation efficiency, improved stability, and reduced innate immune recognition, leading to stronger and more sustained luciferase expression.

Modified Nucleotides: It contains N1-Methylpseudo-UTP modified nucleotides, which decreases immunogenicity, enhances mRNA stability, and increases translational efficiency, resulting in more reliable and reproducible protein yield.

poly(A) tail: It contains an optimized poly(A) tail of approximately 100 nucleotides. This specific length is engineered to maximize transcript stability by resisting degradation and to synergize with the 5' cap for superior, sustained translation efficiency, ensuring robust protein yield in your applications.

Description

mRNA Length

1113 nucleotides

Concentration

~1 mg/mL

Excitation max (nm)

434 nm (mTurquoise2)

Emission max (nm)

474 nm (mTurquoise2)

Buffer

1 mM Sodium Citrate, pH 6.4

Storage

-40°C or below

General tips

Please dissolve it on ice and protect from RNase carefully. Avoid repeated freeze/thaw cycles as possible. Don’t vortex. Upon first use, centrifuge the tube softly and aliquot it into several single use portions. Use RNase-free reagents and materials with appropriate RNase-free technique. Don’t add to the media with serum unless mixing with a transfection reagent.

Shipping Condition

ship with dry ice

Quality Control

Quality Control & MSDS

View current batch:
 

Biological Activity

FAQ

1. How do I choose the right RNA product for my research?

It can be based on your experimental goals:

  • For Tracking Transfection and Translation Efficiency: APExBIO Reporter Gene mRNAs (e.g. EGFP, Firefly Luciferase mRNA) are commonly used to track transfection efficiency and protein expression duration; evaluate gene expression and cell viability; study mRNA localization and bio-distribution via in vivo imaging; optimize transfection conditions and validate LNP delivery system.
  • For Gene Editing, Functional Studies and Gene Therapy Research: APExBIO offers various functional protein mRNAs, involving tumor suppressors (e.g. p53, PTEN), cytokines (e.g. IL-12, IL-10), gene-editing tools (e.g. spCas9, Cre Recombinase), gene replacement protein (e.g. EPO), and antigens (e.g. OVA, SARS-CoV-2 Spike).
  • For Sustained Protein Expression: APExBIO Self-amplifying RNA (saRNA) and Circular RNA (circRNA) are recommended for applications requiring prolonged protein expression. saRNA enables lasting and strong protein expression at lower doses, while circRNA has enhanced structural stability and extended expression duration.
2. What are the key advantages of APExBIO mRNA products?
  • Advanced Capping Technology: Utilizes Cap 1 structure (EZ Cap™ Cap) to achieve enhanced translation efficiency and minimizing activation of the host innate immune response. The capping efficiency can reach 90–99%.
  • Diverse Modification Options: Provides a range of modified nucleotides, such as m1Ψ B8049, 5-moUTP B8061 and Cy5-UTP B8333, which reduce immunogenicity, improve mRNA stability, and maximize protein expression levels.
  • Stringent Quality Control: Each batch undergoes rigorous quality assessment including capping efficiency, purity, integrity, and sterility to ensure batch-to-batch consistency.